nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HTR2C—metabolic syndrome X	0.686	1	CbGaD
Loxapine—SLC6A2—sympathetic nervous system—metabolic syndrome X	0.00829	0.0843	CbGeAlD
Loxapine—HTR7—sympathetic nervous system—metabolic syndrome X	0.00799	0.0812	CbGeAlD
Loxapine—HTR2A—arteriole—metabolic syndrome X	0.00782	0.0795	CbGeAlD
Loxapine—SLC6A2—autonomic nervous system—metabolic syndrome X	0.00557	0.0567	CbGeAlD
Loxapine—HTR7—autonomic nervous system—metabolic syndrome X	0.00537	0.0546	CbGeAlD
Loxapine—HTR2A—sympathetic nervous system—metabolic syndrome X	0.00498	0.0507	CbGeAlD
Loxapine—HTR1B—artery—metabolic syndrome X	0.00395	0.0402	CbGeAlD
Loxapine—HTR1D—artery—metabolic syndrome X	0.00382	0.0389	CbGeAlD
Loxapine—HTR2A—autonomic nervous system—metabolic syndrome X	0.00335	0.0341	CbGeAlD
Loxapine—HTR1B—blood vessel—metabolic syndrome X	0.00308	0.0313	CbGeAlD
Loxapine—HTR7—artery—metabolic syndrome X	0.00305	0.031	CbGeAlD
Loxapine—HTR1D—blood vessel—metabolic syndrome X	0.00298	0.0303	CbGeAlD
Loxapine—Olanzapine—FMO3—metabolic syndrome X	0.00263	0.275	CrCbGaD
Loxapine—HTR7—endothelium—metabolic syndrome X	0.00257	0.0262	CbGeAlD
Loxapine—HTR7—blood vessel—metabolic syndrome X	0.00237	0.0241	CbGeAlD
Loxapine—HRH2—cardiovascular system—metabolic syndrome X	0.00208	0.0212	CbGeAlD
Loxapine—HTR2A—artery—metabolic syndrome X	0.0019	0.0193	CbGeAlD
Loxapine—ADRA1B—kidney—metabolic syndrome X	0.00178	0.0181	CbGeAlD
Loxapine—HTR2A—endothelium—metabolic syndrome X	0.0016	0.0163	CbGeAlD
Loxapine—HTR2A—blood vessel—metabolic syndrome X	0.00148	0.015	CbGeAlD
Loxapine—HTR1B—cardiovascular system—metabolic syndrome X	0.00137	0.014	CbGeAlD
Loxapine—Clozapine—FMO3—metabolic syndrome X	0.00137	0.143	CrCbGaD
Loxapine—CHRM2—cardiovascular system—metabolic syndrome X	0.00137	0.0139	CbGeAlD
Loxapine—HTR1D—cardiovascular system—metabolic syndrome X	0.00133	0.0135	CbGeAlD
Loxapine—HTR1D—kidney—metabolic syndrome X	0.0013	0.0132	CbGeAlD
Loxapine—ADRB1—cardiovascular system—metabolic syndrome X	0.00129	0.0131	CbGeAlD
Loxapine—HRH2—liver—metabolic syndrome X	0.00129	0.0131	CbGeAlD
Loxapine—CHRM1—cardiovascular system—metabolic syndrome X	0.00124	0.0126	CbGeAlD
Loxapine—ADRB1—adipose tissue—metabolic syndrome X	0.00114	0.0116	CbGeAlD
Loxapine—HTR1A—cardiovascular system—metabolic syndrome X	0.00111	0.0113	CbGeAlD
Loxapine—CHRM3—kidney—metabolic syndrome X	0.00109	0.0111	CbGeAlD
Loxapine—HTR7—cardiovascular system—metabolic syndrome X	0.00106	0.0108	CbGeAlD
Loxapine—HTR7—kidney—metabolic syndrome X	0.00104	0.0105	CbGeAlD
Loxapine—ADRA1A—cardiovascular system—metabolic syndrome X	0.00102	0.0104	CbGeAlD
Loxapine—Asenapine—HTR2C—metabolic syndrome X	0.000984	0.103	CrCbGaD
Loxapine—CHRM3—adipose tissue—metabolic syndrome X	0.000981	0.00997	CbGeAlD
Loxapine—ADRA2C—kidney—metabolic syndrome X	0.000952	0.00968	CbGeAlD
Loxapine—ADRA1A—adipose tissue—metabolic syndrome X	0.0009	0.00915	CbGeAlD
Loxapine—Chest discomfort—Metformin—metabolic syndrome X	0.00086	0.0793	CcSEcCtD
Loxapine—ADRA2C—adipose tissue—metabolic syndrome X	0.000858	0.00872	CbGeAlD
Loxapine—HRH1—adipose tissue—metabolic syndrome X	0.000697	0.00709	CbGeAlD
Loxapine—ADRA2A—adipose tissue—metabolic syndrome X	0.000685	0.00696	CbGeAlD
Loxapine—Lightheadedness—Metformin—metabolic syndrome X	0.000681	0.0628	CcSEcCtD
Loxapine—HTR2A—cardiovascular system—metabolic syndrome X	0.00066	0.00671	CbGeAlD
Loxapine—HTR7—liver—metabolic syndrome X	0.000655	0.00666	CbGeAlD
Loxapine—HTR2A—kidney—metabolic syndrome X	0.000646	0.00657	CbGeAlD
Loxapine—ADRA1A—liver—metabolic syndrome X	0.000631	0.00642	CbGeAlD
Loxapine—Nasal congestion—Metformin—metabolic syndrome X	0.000606	0.0559	CcSEcCtD
Loxapine—ADRA2C—liver—metabolic syndrome X	0.000602	0.00612	CbGeAlD
Loxapine—Cyproheptadine—HTR2C—metabolic syndrome X	0.000565	0.059	CrCbGaD
Loxapine—Olanzapine—HTR2C—metabolic syndrome X	0.000547	0.0572	CrCbGaD
Loxapine—Trazodone—HTR2C—metabolic syndrome X	0.000529	0.0552	CrCbGaD
Loxapine—Thiothixene—HTR2C—metabolic syndrome X	0.000495	0.0518	CrCbGaD
Loxapine—Prochlorperazine—HTR2C—metabolic syndrome X	0.000473	0.0495	CrCbGaD
Loxapine—Amoxapine—HTR2C—metabolic syndrome X	0.000435	0.0455	CrCbGaD
Loxapine—Drowsiness—Metformin—metabolic syndrome X	0.000426	0.0392	CcSEcCtD
Loxapine—HTR2A—liver—metabolic syndrome X	0.000408	0.00415	CbGeAlD
Loxapine—Hepatitis—Metformin—metabolic syndrome X	0.000382	0.0352	CcSEcCtD
Loxapine—Hypoaesthesia—Metformin—metabolic syndrome X	0.00038	0.0351	CcSEcCtD
Loxapine—Angiopathy—Metformin—metabolic syndrome X	0.000347	0.032	CcSEcCtD
Loxapine—Mediastinal disorder—Metformin—metabolic syndrome X	0.000344	0.0318	CcSEcCtD
Loxapine—Trifluoperazine—HTR2C—metabolic syndrome X	0.000342	0.0358	CrCbGaD
Loxapine—Quetiapine—HTR2C—metabolic syndrome X	0.000332	0.0347	CrCbGaD
Loxapine—Dysgeusia—Metformin—metabolic syndrome X	0.000326	0.03	CcSEcCtD
Loxapine—Muscle spasms—Metformin—metabolic syndrome X	0.00032	0.0295	CcSEcCtD
Loxapine—Vision blurred—Metformin—metabolic syndrome X	0.000313	0.0289	CcSEcCtD
Loxapine—Tremor—Metformin—metabolic syndrome X	0.000312	0.0287	CcSEcCtD
Loxapine—Syncope—Metformin—metabolic syndrome X	0.000298	0.0275	CcSEcCtD
Loxapine—Loss of consciousness—Metformin—metabolic syndrome X	0.000292	0.027	CcSEcCtD
Loxapine—Hypertension—Metformin—metabolic syndrome X	0.000287	0.0265	CcSEcCtD
Loxapine—Clozapine—HTR2C—metabolic syndrome X	0.000286	0.0298	CrCbGaD
Loxapine—Chest pain—Metformin—metabolic syndrome X	0.000283	0.0261	CcSEcCtD
Loxapine—Oedema—Metformin—metabolic syndrome X	0.000271	0.025	CcSEcCtD
Loxapine—Shock—Metformin—metabolic syndrome X	0.000267	0.0246	CcSEcCtD
Loxapine—Nervous system disorder—Metformin—metabolic syndrome X	0.000266	0.0245	CcSEcCtD
Loxapine—Thrombocytopenia—Metformin—metabolic syndrome X	0.000266	0.0245	CcSEcCtD
Loxapine—Hypotension—Metformin—metabolic syndrome X	0.000254	0.0234	CcSEcCtD
Loxapine—Paraesthesia—Metformin—metabolic syndrome X	0.000244	0.0225	CcSEcCtD
Loxapine—Dyspnoea—Metformin—metabolic syndrome X	0.000242	0.0223	CcSEcCtD
Loxapine—Somnolence—Metformin—metabolic syndrome X	0.000241	0.0223	CcSEcCtD
Loxapine—Olanzapine—ALB—metabolic syndrome X	0.000238	0.0249	CrCbGaD
Loxapine—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.000234	0.0216	CcSEcCtD
Loxapine—Fatigue—Metformin—metabolic syndrome X	0.000234	0.0216	CcSEcCtD
Loxapine—Constipation—Metformin—metabolic syndrome X	0.000232	0.0214	CcSEcCtD
Loxapine—Feeling abnormal—Metformin—metabolic syndrome X	0.000224	0.0206	CcSEcCtD
Loxapine—Thiothixene—ALB—metabolic syndrome X	0.000216	0.0226	CrCbGaD
Loxapine—Asthenia—Metformin—metabolic syndrome X	0.000195	0.018	CcSEcCtD
Loxapine—Pruritus—Metformin—metabolic syndrome X	0.000192	0.0177	CcSEcCtD
Loxapine—Dizziness—Metformin—metabolic syndrome X	0.00018	0.0166	CcSEcCtD
Loxapine—Vomiting—Metformin—metabolic syndrome X	0.000173	0.0159	CcSEcCtD
Loxapine—Rash—Metformin—metabolic syndrome X	0.000171	0.0158	CcSEcCtD
Loxapine—Dermatitis—Metformin—metabolic syndrome X	0.000171	0.0158	CcSEcCtD
Loxapine—Headache—Metformin—metabolic syndrome X	0.00017	0.0157	CcSEcCtD
Loxapine—Nausea—Metformin—metabolic syndrome X	0.000161	0.0149	CcSEcCtD
Loxapine—Diazepam—ALB—metabolic syndrome X	0.000126	0.0132	CrCbGaD
Loxapine—HTR1D—GPCR downstream signaling—AKT1—metabolic syndrome X	1.1e-05	5.66e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—NOS3—metabolic syndrome X	1.1e-05	5.65e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—APOE—metabolic syndrome X	1.1e-05	5.65e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—LEP—metabolic syndrome X	1.1e-05	5.65e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—LEP—metabolic syndrome X	1.1e-05	5.63e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—APOE—metabolic syndrome X	1.1e-05	5.63e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IGF1—metabolic syndrome X	1.1e-05	5.62e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—INS—metabolic syndrome X	1.09e-05	5.61e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—APOA1—metabolic syndrome X	1.09e-05	5.61e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—IL6—metabolic syndrome X	1.09e-05	5.61e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—IL6—metabolic syndrome X	1.09e-05	5.6e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—APOA1—metabolic syndrome X	1.09e-05	5.6e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—INS—metabolic syndrome X	1.09e-05	5.58e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IRS1—metabolic syndrome X	1.09e-05	5.58e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—APOA1—metabolic syndrome X	1.09e-05	5.58e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—LEP—metabolic syndrome X	1.09e-05	5.57e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—APOE—metabolic syndrome X	1.09e-05	5.57e-05	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL6—metabolic syndrome X	1.09e-05	5.57e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL6—metabolic syndrome X	1.08e-05	5.57e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—APOA1—metabolic syndrome X	1.08e-05	5.56e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—APOE—metabolic syndrome X	1.08e-05	5.56e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—LEP—metabolic syndrome X	1.08e-05	5.56e-05	CbGpPWpGaD
Loxapine—HTR1B—GPCR downstream signaling—AKT1—metabolic syndrome X	1.08e-05	5.54e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCL2—metabolic syndrome X	1.08e-05	5.52e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—APOA1—metabolic syndrome X	1.07e-05	5.51e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCL2—metabolic syndrome X	1.07e-05	5.49e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—APOA1—metabolic syndrome X	1.07e-05	5.49e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL6—metabolic syndrome X	1.06e-05	5.45e-05	CbGpPWpGaD
Loxapine—DRD4—GPCR downstream signaling—AKT1—metabolic syndrome X	1.06e-05	5.45e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—INS—metabolic syndrome X	1.06e-05	5.43e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IGF1—metabolic syndrome X	1.06e-05	5.43e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IGF1—metabolic syndrome X	1.05e-05	5.4e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—SERPINE1—metabolic syndrome X	1.05e-05	5.39e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PPARG—metabolic syndrome X	1.05e-05	5.38e-05	CbGpPWpGaD
Loxapine—CHRM4—GPCR downstream signaling—AKT1—metabolic syndrome X	1.05e-05	5.38e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL6—metabolic syndrome X	1.04e-05	5.36e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—INS—metabolic syndrome X	1.04e-05	5.35e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCL2—metabolic syndrome X	1.04e-05	5.34e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—SERPINE1—metabolic syndrome X	1.04e-05	5.34e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL6—metabolic syndrome X	1.03e-05	5.29e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—INS—metabolic syndrome X	1.03e-05	5.28e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—ALB—metabolic syndrome X	1.03e-05	5.27e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AGT—metabolic syndrome X	1.03e-05	5.27e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCL2—metabolic syndrome X	1.02e-05	5.26e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IGF1—metabolic syndrome X	1.02e-05	5.25e-05	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—AKT1—metabolic syndrome X	1.02e-05	5.25e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PTGS2—metabolic syndrome X	1.01e-05	5.21e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—AKT1—metabolic syndrome X	1.01e-05	5.18e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IGF1—metabolic syndrome X	1.01e-05	5.17e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—AKT1—metabolic syndrome X	1.01e-05	5.17e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—LEP—metabolic syndrome X	1.01e-05	5.16e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—APOE—metabolic syndrome X	1.01e-05	5.16e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—SERPINE1—metabolic syndrome X	1e-05	5.16e-05	CbGpPWpGaD
Loxapine—CHRM5—GPCR downstream signaling—AKT1—metabolic syndrome X	1e-05	5.15e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IRS1—metabolic syndrome X	1e-05	5.15e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NOS3—metabolic syndrome X	1e-05	5.15e-05	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—AKT1—metabolic syndrome X	1e-05	5.14e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—AKT1—metabolic syndrome X	1e-05	5.14e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—SERPINE1—metabolic syndrome X	9.99e-06	5.13e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—APOA1—metabolic syndrome X	9.94e-06	5.11e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NOS3—metabolic syndrome X	9.93e-06	5.1e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL6—metabolic syndrome X	9.87e-06	5.07e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IRS1—metabolic syndrome X	9.86e-06	5.06e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IRS1—metabolic syndrome X	9.84e-06	5.05e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—NOS3—metabolic syndrome X	9.82e-06	5.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IRS1—metabolic syndrome X	9.81e-06	5.04e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—AKT1—metabolic syndrome X	9.79e-06	5.03e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IRS1—metabolic syndrome X	9.78e-06	5.02e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—SERPINE1—metabolic syndrome X	9.72e-06	4.99e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IRS1—metabolic syndrome X	9.68e-06	4.97e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IRS1—metabolic syndrome X	9.66e-06	4.96e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—AKT1—metabolic syndrome X	9.64e-06	4.95e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—INS—metabolic syndrome X	9.6e-06	4.93e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NOS3—metabolic syndrome X	9.59e-06	4.92e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—SERPINE1—metabolic syndrome X	9.56e-06	4.91e-05	CbGpPWpGaD
Loxapine—DRD1—GPCR downstream signaling—AKT1—metabolic syndrome X	9.55e-06	4.91e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NOS3—metabolic syndrome X	9.54e-06	4.9e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—AKT1—metabolic syndrome X	9.51e-06	4.88e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL6—metabolic syndrome X	9.45e-06	4.85e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—INS—metabolic syndrome X	9.44e-06	4.85e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCL2—metabolic syndrome X	9.44e-06	4.85e-05	CbGpPWpGaD
Loxapine—DRD3—GPCR downstream signaling—AKT1—metabolic syndrome X	9.43e-06	4.84e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—INS—metabolic syndrome X	9.42e-06	4.84e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—ALB—metabolic syndrome X	9.42e-06	4.84e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL6—metabolic syndrome X	9.4e-06	4.83e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—INS—metabolic syndrome X	9.39e-06	4.82e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—INS—metabolic syndrome X	9.36e-06	4.81e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCL2—metabolic syndrome X	9.29e-06	4.77e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IGF1—metabolic syndrome X	9.28e-06	4.77e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL6—metabolic syndrome X	9.28e-06	4.76e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NOS3—metabolic syndrome X	9.28e-06	4.76e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—INS—metabolic syndrome X	9.27e-06	4.76e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCL2—metabolic syndrome X	9.27e-06	4.76e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—INS—metabolic syndrome X	9.25e-06	4.75e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCL2—metabolic syndrome X	9.24e-06	4.75e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCL2—metabolic syndrome X	9.21e-06	4.73e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IGF1—metabolic syndrome X	9.14e-06	4.69e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NOS3—metabolic syndrome X	9.13e-06	4.69e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCL2—metabolic syndrome X	9.12e-06	4.69e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IGF1—metabolic syndrome X	9.12e-06	4.68e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—AKT1—metabolic syndrome X	9.1e-06	4.68e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCL2—metabolic syndrome X	9.1e-06	4.67e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IGF1—metabolic syndrome X	9.09e-06	4.67e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IGF1—metabolic syndrome X	9.06e-06	4.65e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—NOS3—metabolic syndrome X	9.01e-06	4.63e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PTGS2—metabolic syndrome X	8.98e-06	4.61e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IRS1—metabolic syndrome X	8.97e-06	4.61e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IGF1—metabolic syndrome X	8.97e-06	4.61e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IGF1—metabolic syndrome X	8.95e-06	4.59e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SERPINE1—metabolic syndrome X	8.82e-06	4.53e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—AKT1—metabolic syndrome X	8.72e-06	4.48e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—AKT1—metabolic syndrome X	8.68e-06	4.45e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SERPINE1—metabolic syndrome X	8.68e-06	4.45e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SERPINE1—metabolic syndrome X	8.66e-06	4.45e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SERPINE1—metabolic syndrome X	8.63e-06	4.43e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SERPINE1—metabolic syndrome X	8.6e-06	4.42e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—INS—metabolic syndrome X	8.59e-06	4.41e-05	CbGpPWpGaD
Loxapine—ADRB1—GPCR downstream signaling—AKT1—metabolic syndrome X	8.59e-06	4.41e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TGFB1—metabolic syndrome X	8.56e-06	4.4e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—AKT1—metabolic syndrome X	8.56e-06	4.4e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TGFB1—metabolic syndrome X	8.56e-06	4.39e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SERPINE1—metabolic syndrome X	8.52e-06	4.37e-05	CbGpPWpGaD
Loxapine—ADRA2B—GPCR downstream signaling—AKT1—metabolic syndrome X	8.51e-06	4.37e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TGFB1—metabolic syndrome X	8.5e-06	4.36e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SERPINE1—metabolic syndrome X	8.49e-06	4.36e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—metabolic syndrome X	8.45e-06	4.34e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCL2—metabolic syndrome X	8.45e-06	4.34e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NOS3—metabolic syndrome X	8.42e-06	4.32e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—metabolic syndrome X	8.41e-06	4.32e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—metabolic syndrome X	8.38e-06	4.3e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—metabolic syndrome X	8.36e-06	4.29e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TGFB1—metabolic syndrome X	8.32e-06	4.27e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IGF1—metabolic syndrome X	8.31e-06	4.27e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NOS3—metabolic syndrome X	8.28e-06	4.25e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NOS3—metabolic syndrome X	8.26e-06	4.24e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTGS2—metabolic syndrome X	8.24e-06	4.23e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NOS3—metabolic syndrome X	8.24e-06	4.23e-05	CbGpPWpGaD
Loxapine—HTR1A—GPCR downstream signaling—AKT1—metabolic syndrome X	8.22e-06	4.22e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NOS3—metabolic syndrome X	8.21e-06	4.22e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TGFB1—metabolic syndrome X	8.19e-06	4.21e-05	CbGpPWpGaD
Loxapine—HTR2C—GPCR downstream signaling—AKT1—metabolic syndrome X	8.17e-06	4.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NOS3—metabolic syndrome X	8.13e-06	4.18e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NOS3—metabolic syndrome X	8.11e-06	4.16e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—metabolic syndrome X	8.09e-06	4.15e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TGFB1—metabolic syndrome X	8.08e-06	4.15e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—metabolic syndrome X	8.05e-06	4.13e-05	CbGpPWpGaD
Loxapine—ADRA2C—GPCR downstream signaling—AKT1—metabolic syndrome X	7.95e-06	4.08e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SERPINE1—metabolic syndrome X	7.89e-06	4.05e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—metabolic syndrome X	7.83e-06	4.02e-05	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—AKT1—metabolic syndrome X	7.82e-06	4.02e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—AKT1—metabolic syndrome X	7.8e-06	4e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—AKT1—metabolic syndrome X	7.76e-06	3.99e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TGFB1—metabolic syndrome X	7.74e-06	3.97e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—AKT1—metabolic syndrome X	7.73e-06	3.97e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—AKT1—metabolic syndrome X	7.71e-06	3.96e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—metabolic syndrome X	7.7e-06	3.95e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NOS3—metabolic syndrome X	7.54e-06	3.87e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—AKT1—metabolic syndrome X	7.46e-06	3.83e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—AKT1—metabolic syndrome X	7.42e-06	3.81e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TGFB1—metabolic syndrome X	7.37e-06	3.79e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TGFB1—metabolic syndrome X	7.27e-06	3.74e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—AKT1—metabolic syndrome X	7.22e-06	3.71e-05	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—AKT1—metabolic syndrome X	7.21e-06	3.7e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—AKT1—metabolic syndrome X	7.1e-06	3.65e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—metabolic syndrome X	7.1e-06	3.65e-05	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—AKT1—metabolic syndrome X	7.1e-06	3.64e-05	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—AKT1—metabolic syndrome X	7.08e-06	3.64e-05	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—AKT1—metabolic syndrome X	7.06e-06	3.62e-05	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—AKT1—metabolic syndrome X	7.04e-06	3.61e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—metabolic syndrome X	6.99e-06	3.59e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—metabolic syndrome X	6.97e-06	3.58e-05	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—AKT1—metabolic syndrome X	6.97e-06	3.58e-05	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—AKT1—metabolic syndrome X	6.95e-06	3.57e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—metabolic syndrome X	6.95e-06	3.57e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—metabolic syndrome X	6.93e-06	3.56e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—metabolic syndrome X	6.86e-06	3.52e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—metabolic syndrome X	6.84e-06	3.51e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—metabolic syndrome X	6.63e-06	3.4e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—metabolic syndrome X	6.57e-06	3.37e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—metabolic syndrome X	6.55e-06	3.36e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—metabolic syndrome X	6.46e-06	3.32e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—metabolic syndrome X	6.45e-06	3.31e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—metabolic syndrome X	6.45e-06	3.31e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—metabolic syndrome X	6.45e-06	3.31e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—metabolic syndrome X	6.43e-06	3.3e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—metabolic syndrome X	6.41e-06	3.29e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—metabolic syndrome X	6.4e-06	3.29e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—metabolic syndrome X	6.39e-06	3.28e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—metabolic syndrome X	6.36e-06	3.26e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—metabolic syndrome X	6.34e-06	3.26e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—metabolic syndrome X	6.33e-06	3.25e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—metabolic syndrome X	6.31e-06	3.24e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—metabolic syndrome X	6.31e-06	3.24e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—metabolic syndrome X	6.27e-06	3.22e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—metabolic syndrome X	6.17e-06	3.17e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—metabolic syndrome X	6.13e-06	3.15e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—metabolic syndrome X	6.09e-06	3.13e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—metabolic syndrome X	6.04e-06	3.1e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—metabolic syndrome X	5.95e-06	3.06e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—metabolic syndrome X	5.95e-06	3.05e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—metabolic syndrome X	5.91e-06	3.03e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—metabolic syndrome X	5.86e-06	3.01e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—metabolic syndrome X	5.83e-06	2.99e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—metabolic syndrome X	5.79e-06	2.97e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—metabolic syndrome X	5.69e-06	2.92e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—metabolic syndrome X	5.62e-06	2.88e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—metabolic syndrome X	5.57e-06	2.86e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—metabolic syndrome X	5.56e-06	2.85e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—metabolic syndrome X	5.48e-06	2.81e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—metabolic syndrome X	5.48e-06	2.81e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—metabolic syndrome X	5.47e-06	2.81e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—metabolic syndrome X	5.45e-06	2.8e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—metabolic syndrome X	5.43e-06	2.79e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—metabolic syndrome X	5.38e-06	2.76e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—metabolic syndrome X	5.38e-06	2.76e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—metabolic syndrome X	5.36e-06	2.75e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—metabolic syndrome X	5.13e-06	2.63e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—metabolic syndrome X	5.1e-06	2.62e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—metabolic syndrome X	5.06e-06	2.6e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—metabolic syndrome X	4.99e-06	2.56e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—metabolic syndrome X	4.98e-06	2.56e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—metabolic syndrome X	4.95e-06	2.54e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—metabolic syndrome X	4.78e-06	2.45e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—metabolic syndrome X	4.75e-06	2.44e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—metabolic syndrome X	4.62e-06	2.37e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—metabolic syndrome X	4.61e-06	2.37e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—metabolic syndrome X	4.57e-06	2.34e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—metabolic syndrome X	4.55e-06	2.34e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—metabolic syndrome X	4.51e-06	2.32e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—metabolic syndrome X	4.41e-06	2.26e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—metabolic syndrome X	4.38e-06	2.25e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—metabolic syndrome X	4.26e-06	2.19e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—metabolic syndrome X	4.2e-06	2.16e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—metabolic syndrome X	4.19e-06	2.15e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—metabolic syndrome X	4.14e-06	2.13e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—metabolic syndrome X	4.13e-06	2.12e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—metabolic syndrome X	4.12e-06	2.11e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—metabolic syndrome X	4.1e-06	2.11e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—metabolic syndrome X	4.09e-06	2.1e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—metabolic syndrome X	4.05e-06	2.08e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—metabolic syndrome X	4.04e-06	2.07e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—metabolic syndrome X	3.87e-06	1.99e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—metabolic syndrome X	3.81e-06	1.95e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—metabolic syndrome X	3.8e-06	1.95e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—metabolic syndrome X	3.79e-06	1.94e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—metabolic syndrome X	3.77e-06	1.94e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—metabolic syndrome X	3.75e-06	1.93e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—metabolic syndrome X	3.74e-06	1.92e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—metabolic syndrome X	3.73e-06	1.91e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—metabolic syndrome X	3.46e-06	1.78e-05	CbGpPWpGaD
